A carregar...
Development of autologous C5 vaccine nanoparticles to reduce intravascular hemolysis in vivo
The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement. In this s...
Na minha lista:
| Publicado no: | ACS Chem Biol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5815388/ https://ncbi.nlm.nih.gov/pubmed/28045484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.6b00994 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|